Literature DB >> 30254003

The Time to and Type of Pancreatic Cancer Recurrence after Surgical Resection: Is Prediction Possible?

Jelena Djokić Kovač1, Philipp Mayer2, Thilo Hackert3, Miriam Klauss2.   

Abstract

RATIONALE AND
OBJECTIVES: To evaluate factors predicting pancreatic cancer recurrence, and to determine the most common appearance of tumor relapse.
MATERIALS AND METHODS: Ninety patients with recurrent pancreatic cancer were retrospectively included in the study. 74.4% had pancreatic head tumors (group 1) and 25.6% pancreatic body and/or tail tumor (group 2). The tumor localization, operative technique, TNM stage, the R-status, tumor grade, lymphovascular, and perineural invasion were recorded. Location of local tumor recurrence, lymph node recurrence, or organ metastases were analyzed on the basis of follow-up CT imaging.
RESULTS: Mean recurrence time was 17.4 ± 13.2 months. The most common recurrence type was local recurrence (84.4%), followed by lymph node (15.5%), liver (14.4%), and lung metastasis (6.7%). The predominant site of local recurrence in pancreatic head tumors was close to superior mesenteric artery, common hepatic artery, and/or celiac artery (57.4%), followed by area defined by portal vein, inferior vena cava, CA or superior mesenteric artery (31.2%). Patients with pancreatic body and/or tail carcinoma had higher incidence (p = 0.003) of metastatic disease comparing to pancreatic head tumors, while resection margin was the most common type of local tumor recurrence, seen in 46.7% cases versus 8.2% of patients with pancreatic head tumors (p < 0.001).
CONCLUSION: The most common recurrence type in patients with resected pancreatic carcinoma was local recurrence along cardinal arteries. The localization of primary tumor influences the type of tumor relapse and site of local recurrence.
Copyright © 2018 The Association of University Radiologists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adenocarcinoma; Computed tomography; Pancreas; Recurrence

Mesh:

Year:  2018        PMID: 30254003     DOI: 10.1016/j.acra.2018.07.025

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  5 in total

1.  Postoperative surveillance of pancreatic ductal adenocarcinoma (PDAC) recurrence: practice pattern on standardized imaging and reporting from the society of abdominal radiology disease focus panel on PDAC.

Authors:  Linda C Chu; Zhen J Wang; Avinash Kambadakone; Elizabeth M Hecht; Jin He; Amol K Narang; Daniel A Laheru; Hina Arif-Tiwari; Priya Bhosale; Candice W Bolan; Olga R Brook; Abraham F Bezuidenhout; Richard K G Do; Samuel J Galgano; Ajit H Goenka; Alexander R Guimaraes; David M Hough; Naveen Kulkarni; Ott Le; Lyndon Luk; Lorenzo Mannelli; Michael Rosenthal; Guillermo Sangster; Zarine K Shah; Erik V Soloff; Parag P Tolat; Marc Zins; Elliot K Fishman; Eric P Tamm; Atif Zaheer
Journal:  Abdom Radiol (NY)       Date:  2022-10-14

2.  Impact of surveillance among patients with resected pancreatic cancer following adjuvant chemotherapy.

Authors:  Selina K Wong; Lovedeep Gondara; Daniel J Renouf; Howard J Lim; Jonathan M Loree; Janine M Davies; Sharlene Gill
Journal:  J Gastrointest Oncol       Date:  2021-04

3.  Additional MRI for initial M-staging in pancreatic cancer: a cost-effectiveness analysis.

Authors:  Felix G Gassert; Sebastian Ziegelmayer; Johanna Luitjens; Florian T Gassert; Fabian Tollens; Johann Rink; Marcus R Makowski; Johannes Rübenthaler; Matthias F Froelich
Journal:  Eur Radiol       Date:  2021-11-27       Impact factor: 7.034

4.  Real-world staging computed tomography scanning technique and important reporting discrepancies in pancreatic ductal adenocarcinoma.

Authors:  Alexander Grogan; Benjamin Loveday; Michael Michael; Hui-Li Wong; Peter Gibbs; Benjamin Thomson; Belinda Lee; Hyun Soo Ko
Journal:  ANZ J Surg       Date:  2022-05-25       Impact factor: 2.025

5.  Risk factors and survival prediction of pancreatic cancer with lung metastases: A population-based study.

Authors:  Zong-Xi Yao; Jun-Hao Tu; Bin Zhou; Yang Huang; Yu-Lin Liu; Xiao-Feng Xue
Journal:  Front Oncol       Date:  2022-09-21       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.